FDA Concern of Breast Implants & Cancer | Breast Implants Cancer Risk

News » FDA Concern of Breast Implants & Cancer | Breast Implants Cancer Risk

Breast Implants Cancer Risk

On Monday, November 26, 2018, NBC Nightly News reported that a rare type of breast cancer linked to breast implants could be more common than doctors and patients may have realized. As of the show's airing, 414 reported cases of Anaplastic large-cell lymphoma (ALCL) have been reported to the FDA. The FDA has confirmed that malignancy of the immune system associated with breast implants has resulted in nine deaths. ALCL is a type of non-Hodgkin's T-cell lymphoma that can develop after receiving breast implants. Rare cancer begins to form in the capsule of the scar tissue around the implant. Symptoms include lumps, pain, fluid build-up, and swelling. In most cases, ALCL is treatable if it recognized early enough. Many of these cases are treated by removing the implant and surrounding scar tissue where cancer developed. In some cases, chemotherapy and radiation are necessary to control the spread of the disease.

Because of limited reporting, there is currently no exact statistic on the number of women suffering from ALCL caused by breast implants. In the Nightly News segment, Lester Holt cited the Associated Press report that started last fall, ""thousands of problems with breast implants flooded the FDA's system. More than 4,000 injury reports filed in the last half of 2017. Another 8,000 in the first six months of 2018. The spike in reports "came to light after the FDA instructed manufacturers in mid-2017 to go back and file individual reports in each case of patient injury, in response to a lawyer’s discovery that reports from his clients weren’t represented in the agency’s data."

The FDA findings suggest that women are much more likely to develop cancer if they receive implants with textured surfaces rather than smooth surfaces. The FDA website stresses that the data is limited and subject to bias, and there is no certainty that one specific surface-type is more likely to result in ALCL than another. The FDA website also states that they "continue to collect and evaluate information about ALCL in women with breast implants". However, since the airing of the NBC report, the FDA has since stated they will not ban the textured breast implants. On May 2, 2019, "the announcement follows a public hearing in March on breast implant safety and the risks of breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, associated with textured implants." The FDA has previously said they do not believe implants "meet the legal standard" to be banned under the Food, Drug, and Cosmetic Act. However, the FDA continued to work on strengthening warnings and evaluate the risks associated.

After extensive research, the FDA requested the implants be taken off the market. On July 24, 2019, Allergan, the manufacturer of textured breast implants, recalled all breast implant products associated with ALCL. Surgeons prefer textured implants to ensure that the implant will stay in place, though smooth implants are more simple to insert and adjust. There is no evidence explaining why textured implants lead to a higher likelihood of developing ALCL, but experts are exploring a theory that has to do with the bodies reaction to the material as the skin tissue regrows around the textured implant in microscopic grooves. There seems to be no greater likelihood of developing cancer based on the actual contents of the implants.

About ALCL

ALCL is a type of non-Hodgkin's T-cell lymphoma that can develop after receiving breast implants. 414 reported cases have been reported to the FDA.

ALCL is a rare form of cancer. Women that have not experienced complications have no reason to remove the implants. But women with breast implants, or women planning on receiving breast implants, should be aware of the potential complications. Women with illnesses, such as ALCL, that have been linked to breast implants met with the Food and Drug Administration in March 2019 to demand changes. The two-day public forum was held by the general and plastic surgery devices panel to "hear from researchers, advocates, patients, and the industry about the implants." The goal of the forum to decide the next steps in exploring the growing evidence that suggests breast implants can lead to adverse health effects. The women who spoke out against industry standards expressed concern about the lack of information provided to those wanting breast implants and calling for a ban one type of implant that is associated with ALCL. Additionally, they asked the panel to disclose all materials used in the implants and enact a black box warning. The warning is the strongest warning the FDA can issue for a pharmaceutical drug or medical device.

In the United States, about 400,000 women get breast implants every year. As the discussion has progressed, we are glad the FDA took the initiative to properly warn women about the risk associated and Allergan heeded the warning.

Fox, Maggie, and Lauren Dunn. “Certain Breast Implants Raise Cancer Risk. But Do Women Know This?” NBCNews.com, NBCUniversal News Group, 26 Nov. 2018, www.nbcnews.com/health/health-news/doctors-patients-raise-alarms-about-cancer-linked-breast-implants-n940181

Grady, Denise, and Roni Caryn Rabin. “Women at Breast Implant Hearing Call for Disclosure of Safety Risks.” The New York Times, The New York Times, 25 Mar. 2019, www.nytimes.com/2019/03/25/health/breast-implants-cancer.html

Share

Related Posts

FDA Approval Process | What is the FDA Drug Approval Process?

June 23, 2020
Learn More

June 23, 2020

FDA Approval Process | What is the FDA Drug Approval Process?

Black Box Warning – The Strongest Consumer Warning FDA Can Issue

September 8, 2017
Learn More

September 8, 2017

Black Box Warning – The Strongest Consumer Warning FDA Can Issue

Should I Report A Drug Injury or Drug Side Effect?

May 17, 2017
Learn More

May 17, 2017

Should I Report A Drug Injury or Drug Side Effect?

FAERS: A Questionable Drug Safety Reporting System

February 19, 2015
Learn More

February 19, 2015

FAERS: A Questionable Drug Safety Reporting System

FDA Approval Process Called Into Question for Unsafe Practices

August 2, 2011
Learn More

August 2, 2011

FDA Approval Process Called Into Question for Unsafe Practices

CLIENT REVIEWS

quotation
Tom Lewis

TorHoerman Law was responsible for handling a medical case for our family. I was extremely impressed with their professionalism and ability to react quickly. They also did a nice job keeping us updated with the case throughout the process. This was the first time experiencing a situation like this and Tor Hoerman law did an excellent job from start to finish.

quotation
Jordan Terry

TorHoerman Law is an extraordinary law firm – a firm that truly makes the client’s best interests the primary concern. Their team of personal injury lawyers are experienced, personable, and well versed in a range of litigation areas. They are supported by a dedicated team of staff that are as equally friendly and helpful. I would recommend TorHoerman Law for any personal injury litigation needs.

quotation
Dave Woodley

All of my questions were answered quickly and in a way I could understand. Steve and the entire staff were friendly and professional.

quotation
Jordan Butler

I highly recommend this law firm! The attorneys and staff at THL worked hard, communicated every step of the process, kept me well informed at all times, and exceeded all expectations! The staff is kind, considerate, professional, and very experienced. Look no further, call now!

quotation
Maddy Moeller

Top-notch, hardworking attorneys!

quotation
Karen Hersman

A wonderful and professional legal team. They helped me when I needed expert legal representation! Thank you TorHoerman Law!

quotation
Angel Truesdale

They contacted me the next day. Very nice people!

quotation
Paul Graegin

The firm went above and beyond. Thank you for everything.

quotation
Carie Terry

The attorneys at THL were extremely helpful with the legal aspects of setting up my small business.

THANK YOU FOR YOUR MESSAGE

One of our associates will follow up with you shortly